DelveInsight has launched a new report on "Radiodermatitis - Market Insights, Epidemiology, and Market Forecast-2032”.
Some of the key facts of the Radiodermatitis Market Report:
- As per a study by Singh M et al. titled, “Radiodermatitis: A Review of Our Current Understanding”, around 95% of cancer patients receiving radiation therapy will develop some form of radiodermatitis, including erythema, dry desquamation, and moist desquamation.
- “Prevention and treatment of acute and chronic radiodermatitis” by Seite S et al. specified that Symptoms of acute radiodermatitis have been classified into three levels; grade 1 (mild erythema), grade 2 (dry desquamation), and grade 3 (severe moist desquamation). Grade 1 skin toxicity still remains a problem for around 90% of patients and grade 2 for 30% of patients.
Key benefits of the report:
- Radiodermatitis market report covers a descriptive overview and comprehensive insight into the Radiodermatitis Epidemiology and Radiodermatitis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Radiodermatitis market report provides insights on the current and emerging therapies.
- Radiodermatitis market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Radiodermatitis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Radiodermatitis market.
Got queries? Click here to know more about the Radiodermatitis Market Landscape.
Radiodermatitis Overview
Radiodermatitis, also known as radiation dermatitis, x-ray dermatitis, radiation skin damage, or radiation burn, is a condition that primarily affects the skin followed by exposure to radiation therapy, it is basically termed as a side effect of radiation treatment. The development and severity of radiodermatitis are associated with multiple patient and treatment factors such as total radiation dose, duration of radiotherapy, and treatment with chemotherapy.
Radiodermatitis Market
The dynamics of the Radiodermatitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies by companies such as Reata Pharmaceuticals, Inc., Noveome Biotherapeutics, and others during the study period 2019-2032.
Radiodermatitis Pipeline Therapies and Key Companies
- Omaveloxolone Lotion: Reata Pharmaceuticals, Inc.
- Biological: ST266: Noveome Biotherapeutics
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Radiodermatitis Patient Share (%) Overview at a Glance
5. Radiodermatitis Market Overview at a Glance
6. Radiodermatitis Disease Background and Overview
7. Radiodermatitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Radiodermatitis
9. Radiodermatitis Current Treatment and Medical Practices
10. Unmet Needs
11. Radiodermatitis Emerging Therapies
12. Radiodermatitis Market Outlook
13. Country-Wise Radiodermatitis Market Analysis (2019–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Radiodermatitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Request for a sample report @https://www.delveinsight.com/sample-request/radiodermatitis-market
Related Reports:
Radiodermatitis Pipeline
"Radiodermatitis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Radiodermatitis market. A detailed picture of the Radiodermatitis pipeline landscape is provided, which includes the disease overview and Radiodermatitis treatment guidelines.
Radiodermatitis Epidemiology
DelveInsight's 'Radiodermatitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Radiodermatitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
